{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:25:57Z","timestamp":1787955957517,"version":"build-2784847793"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007687","name":"Swedish Society of Medicine","doi-asserted-by":"publisher","award":["SLS-971390"],"award-info":[{"award-number":["SLS-971390"]}],"id":[{"id":"10.13039\/501100007687","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Swedish Eye Foundation","award":["2022-05-09"],"award-info":[{"award-number":["2022-05-09"]}]},{"name":"Region Stockholm","award":["FoUI-981345"],"award-info":[{"award-number":["FoUI-981345"]}]},{"DOI":"10.13039\/501100002794","name":"Swedish Cancer Society","doi-asserted-by":"publisher","award":["20 0798 Fk"],"award-info":[{"award-number":["20 0798 Fk"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Crown Princess Margareta Foundation for the Visually Impaired","award":["2022-017"],"award-info":[{"award-number":["2022-017"]}]},{"name":"Carmen and Bertil Regn\u00e9r Foundation","award":["2022-00071"],"award-info":[{"award-number":["2022-00071"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Uveal melanoma has a high propensity for metastatic spread. Yet, the comprehensive causes of death in a large consecutive cohort followed from diagnosis to death remain unknown.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>All Swedish patients diagnosed with melanoma involving the iris, choroid, and\/or ciliary body after January 1, 1960, were assessed for this study. Sequential inclusion was halted upon encountering the first surviving patient during data collection. Causes of death were collected from the National Cause of Death Registry and audited by analysis of up to 15 causative diagnoses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 1530 patients were included, each histopathologically verified with primary uveal melanoma. Mortality from metastatic uveal melanoma was 31% at 5\u2009years, 40% at 10\u2009years, 45% at 20\u2009years, 47% at 30\u2009years, and 48% between 40 and 60\u2009years post-diagnosis. Notably, the longest period between diagnosis and metastatic fatality was 49.6\u2009years. Additionally, 186 other causes of death were recorded, with cardiovascular diseases constituting 26%, other cancers 10%, stroke 6%, dementias 2%, and lower respiratory infections 2% of total mortalities. Mortality from colorectal, lung, prostate, and stomach carcinomas over 60\u2009years were 1.4%, 1.4%, 1.2%, and 0.9%, with metastatic uveal melanoma being the leading cumulative and annual cause of death for the initial 41 and 5 years post-diagnosis, respectively.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In this large consecutive cohort, half of the included patients ultimately succumbed to metastatic uveal melanoma, with deaths occurring up to 50\u2009years after diagnosis. One-quarter and one-tenth of patients died from cardiovascular diseases and other cancers, respectively.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jncics\/pkad097","type":"journal-article","created":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T18:25:11Z","timestamp":1700159111000},"source":"Crossref","is-referenced-by-count":22,"title":["Comprehensive causes of death in uveal melanoma: mortality in 1530 consecutively diagnosed patients followed until death"],"prefix":"10.1093","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9401-8911","authenticated-orcid":false,"given":"Gustav","family":"St\u00e5lhammar","sequence":"first","affiliation":[{"name":"Department of Clinical Neuroscience, Division of Eye and Vision, Karolinska Institutet , Stockholm, Sweden"},{"name":"Ocular Oncology Service and St. Erik Ophthalmic Pathology Laboratory, St. Erik Eye Hospital , Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"issue":"13","key":"2023121605534540600_pkad097-B1","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","article-title":"Overall survival benefit with tebentafusp in metastatic uveal melanoma","volume":"385","author":"Nathan","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"2023121605534540600_pkad097-B2","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1001\/jamaophthalmol.2014.77","article-title":"Age, survival predictors, and metastatic death in patients with choroidal melanoma: tentative evidence of a therapeutic effect on survival","volume":"132","author":"Damato","year":"2014","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"2023121605534540600_pkad097-B3","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3109\/08820538.2016.1154176","article-title":"Disparities in uveal melanoma: patient characteristics","volume":"31","author":"Nichols","year":"2016","journal-title":"Semin Ophthalmol"},{"issue":"1","key":"2023121605534540600_pkad097-B4","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/PAT.0b013e32835c6505","article-title":"Pathology and genetics of uveal melanoma","volume":"45","author":"Griewank","year":"2013","journal-title":"Pathology"},{"issue":"1","key":"2023121605534540600_pkad097-B5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40487-018-0056-8","article-title":"Uveal melanoma: a review of the literature","volume":"6","author":"Singh","year":"2018","journal-title":"Oncol Ther"},{"issue":"1","key":"2023121605534540600_pkad097-B6","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41572-020-0158-0","article-title":"Uveal melanoma","volume":"6","author":"Jager","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"2023121605534540600_pkad097-B7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.preteyeres.2011.05.003","article-title":"Estimating prognosis for survival after treatment of choroidal melanoma","volume":"30","author":"Damato","year":"2011","journal-title":"Prog Retin Eye Res"},{"issue":"7","key":"2023121605534540600_pkad097-B8","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1001\/jamaophthalmol.2015.0887","article-title":"Long-term risk of melanoma-related mortality for patients with uveal melanoma treated with proton beam therapy","volume":"133","author":"Lane","year":"2015","journal-title":"JAMA Ophthalmol"},{"issue":"12","key":"2023121605534540600_pkad097-B9","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.124.12.1684","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. twelve-year mortality rates and prognostic factors: COMS Report No. 28","volume":"124","author":"Collaborative Ocular Melanoma Study Group","year":"2006","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"2023121605534540600_pkad097-B10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1159\/000492391","article-title":"Uveal melanoma in Ireland","volume":"5","author":"Baily","year":"2019","journal-title":"Ocul Oncol Pathol"},{"issue":"11","key":"2023121605534540600_pkad097-B11","doi-asserted-by":"crossref","first-page":"4651","DOI":"10.1167\/iovs.03-0538","article-title":"Very long-term prognosis of patients with malignant uveal melanoma","volume":"44","author":"Kujala","year":"2003","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"2","key":"2023121605534540600_pkad097-B12","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jamaophthalmol.2015.5233","article-title":"Long-term risk of melanoma-related mortality after uveal melanoma","volume":"134","author":"Kivela","year":"2016","journal-title":"JAMA Ophthalmol"},{"issue":"1","key":"2023121605534540600_pkad097-B13","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1093\/ndt\/gfq661","article-title":"The analysis of competing events like cause-specific mortality\u2014beware of the Kaplan-Meier method","volume":"26","author":"Verduijn","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"2023121605534540600_pkad097-B14","doi-asserted-by":"crossref","first-page":"6700","DOI":"10.1002\/cam4.5458","article-title":"Sex-based differences in early and late uveal melanoma-related mortality","volume":"12","author":"Stalhammar","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"2023121605534540600_pkad097-B15","doi-asserted-by":"crossref","first-page":"926034","DOI":"10.3389\/fmed.2022.926034","article-title":"Trends in uveal melanoma presentation and survival during five decades: a nationwide survey of 3898 Swedish patients","volume":"9","author":"Gill","year":"2022","journal-title":"Front Med"},{"key":"2023121605534540600_pkad097-B16","first-page":"1","volume-title":"Population Statistics","author":"Statistics Sweden","year":"2020"},{"issue":"4","key":"2023121605534540600_pkad097-B17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","article-title":"Competing risk analysis using R: an easy guide for clinicians","volume":"40","author":"Scrucca","year":"2007","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2023121605534540600_pkad097-B18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43856-022-00082-y","article-title":"Long-term relative survival in uveal melanoma: a systematic review and meta-analysis","volume":"2","author":"St\u00e5lhammar","year":"2022","journal-title":"Commun Med"},{"issue":"1","key":"2023121605534540600_pkad097-B19","doi-asserted-by":"crossref","first-page":"11297","DOI":"10.1038\/s41598-020-68232-7","article-title":"Forty-year prognosis after plaque brachytherapy of uveal melanoma","volume":"10","author":"Stalhammar","year":"2020","journal-title":"Sci Rep"},{"key":"2023121605534540600_pkad097-B20","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.atherosclerosis.2020.08.014","article-title":"Lifetime risk predictions for cardiovascular diseases: competing risks analyses on a population-based cohort in Sweden","volume":"312","author":"Stenling","year":"2020","journal-title":"Atherosclerosis"},{"issue":"6","key":"2023121605534540600_pkad097-B21","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"2023121605534540600_pkad097-B22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5694\/mja2.50376","article-title":"Is the risk of cancer in Australia overstated? The importance of competing mortality for estimating lifetime risk","volume":"212","author":"Bach","year":"2020","journal-title":"Med J Aust"},{"issue":"3","key":"2023121605534540600_pkad097-B23","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"2023121605534540600_pkad097-B24","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/bjc.2016.304","article-title":"Cancer incidence and mortality projections in the UK until 2035","volume":"115","author":"Smittenaar","year":"2016","journal-title":"Br J Cancer"},{"issue":"1","key":"2023121605534540600_pkad097-B25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2023121605534540600_pkad097-B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers14020284","article-title":"Risk of new primary cancer in patients with posterior uveal melanoma: a national cohort study","volume":"14","author":"Bagger","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2023121605534540600_pkad097-B27","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1167\/iovs.05-0884","article-title":"Uveal melanoma: a study on incidence of additional cancers in the Swedish population","volume":"47","author":"Bergman","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2023121605534540600_pkad097-B28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ajo.2016.02.022","article-title":"Second primary neoplasms in patients with uveal melanoma: a SEER database analysis","volume":"165","author":"Lains","year":"2016","journal-title":"Am J Ophthalmol"},{"issue":"6","key":"2023121605534540600_pkad097-B29","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1159\/000497186","article-title":"No gender differences in long-term survival after brachytherapy of 1,541 patients with uveal melanoma","volume":"5","author":"Stalhammar","year":"2019","journal-title":"Ocul Oncol Pathol"},{"issue":"1","key":"2023121605534540600_pkad097-B30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1111\/aos.15210","article-title":"A prognostic classification system for uveal melanoma based on a combination of patient age and sex, the American Joint Committee on Cancer and the Cancer Genome Atlas models","volume":"101","author":"Gill","year":"2022","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"2023121605534540600_pkad097-B31","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archopht.119.7.969","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18","volume":"119","author":"Diener-West","year":"2001","journal-title":"Arch Ophthalmol"},{"issue":"21","key":"2023121605534540600_pkad097-B32","doi-asserted-by":"crossref","first-page":"3344","DOI":"10.1002\/cncr.30258","article-title":"Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies","volume":"122","author":"Algazi","year":"2016","journal-title":"Cancer"},{"issue":"8","key":"2023121605534540600_pkad097-B33","doi-asserted-by":"publisher","first-page":"e1474","DOI":"10.1111\/aos.14847","article-title":"Posterior uveal melanoma incidence and survival by AJCC tumour size in a 70-year nationwide cohort","volume":"99","author":"Smidt-Nielsen","year":"2021","journal-title":"Acta Ophthalmol"},{"issue":"16","key":"2023121605534540600_pkad097-B34","doi-asserted-by":"publisher","first-page":"3042","DOI":"10.1200\/JClinOncol.22.01705:JCO2201705","article-title":"Isolated hepatic perfusion with melphalan for patients with isolated uveal melanoma liver metastases: a multicenter, randomized, open-label, phase III trial (the SCANDIUM trial)","volume":"41","author":"Olofsson Bagge","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["JNCI Cancer Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jncics\/advance-article-pdf\/doi\/10.1093\/jncics\/pkad097\/53474298\/pkad097.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/7\/6\/pkad097\/54533354\/pkad097.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jncics\/article-pdf\/7\/6\/pkad097\/54533354\/pkad097.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,16]],"date-time":"2023-12-16T05:54:37Z","timestamp":1702706077000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jncics\/article\/doi\/10.1093\/jncics\/pkad097\/7424715"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,31]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,10,31]]}},"URL":"https:\/\/doi.org\/10.1093\/jncics\/pkad097","relation":{},"ISSN":["2515-5091"],"issn-type":[{"value":"2515-5091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,12,1]]},"published":{"date-parts":[[2023,10,31]]},"article-number":"pkad097"}}